相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020
Hye-Kyung Jung et al.
GUT AND LIVER (2021)
Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects
Jong-Lyul Ghim et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Su1382 INEFFECTIVENESS OF 14-DAY VONOPRAZAN-BASED DUAL THERAPY AND VONOPRAZAN-BASED TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION IN AREA OF HIGH CLARITHROMYCIN RESISTANCE: A PROSPECTIVE RANDOMIZED STUDY
Likhasit Sanglutong et al.
GASTROENTEROLOGY (2020)
Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study
Jeong Hoon Lee et al.
HELICOBACTER (2019)
Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects
Sungpil Han et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility
Nobuyuki Takahashi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication
Hiroki Tanabe et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2018)
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
P. Malfertheiner et al.
GUT (2017)
Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints
Teresa Alarcon et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2017)
Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
Shou Quan Dong et al.
HELICOBACTER (2017)
Selective killing of Helicobacter pylori with pH-responsive helix-coil conformation transitionable antimicrobial polypeptides
Menghua Xiong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Review article: the global emergence of Helicobacter pylori antibiotic resistance
I. Thung et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
Hirotoshi Echizen
CLINICAL PHARMACOKINETICS (2016)
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
Kazunari Murakami et al.
GUT (2016)
Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases
Nobuhiro Inatomi et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Kyoto global consensus report on Helicobacter pylori gastritis
Kentaro Sugano et al.
GUT (2015)
Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition
Sang Gyun Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan
Tsutomu Nishida et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Helicobacter pylori infection and the development of gastric cancer.
N Uemura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Comparison of covalent with reversible inhibitor binding sites of the gastric H,K-ATPase by site-directed mutagenesis
N Lambrecht et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
